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Introduction
The positron emission tomography (PET) Centre of the
Masaryk Memorial Cancer Institute was brought into operation in
September 2003, as a second PET Centre in the Czech Republic.
The department employs the Siemens E.CAT Accel PET camera
with LSO crystals. The 18F-fluoro-2-deoxyglucose (18F-FDG) rep-
resents the only PET tracer used so far, delivered twice a day from
its producer, the Nuclear Research Institute Rez plc (Prague, Czech
Republic).
The Thema Synergy semi-automatic system installed in Feb-
ruary 2004 simplified the preparation of the pharmaceutical for
each patient, and helped to markedly reduce the technologists
hand absorbed doses.
Administered activity varies depending on the type of study.
For a whole-body examination, an average of 370 MBq of
18F-FDG is applied; for a PET scan of the brain or the myocardi-
um, an average of 200 MBq of 18F-FDG is applied per standard
patient with body weight of 70 kg.
An average of 1718 examinations are performed daily from
the 18F-FDG supplied  including Saturdays and Sundays
 adding to a total of approximately 480 examinations per month.
From September 2003 through November 2005 more than 10,000
examinations have been performed. Each PET study is evaluated
independently by two physicians specializing in nuclear medicine.
The picture documentation of each study (raw data, representa-
tive slices, the pseudo-three-dimensional maximum intensity pro-
jections (MIP), semi-quantification of the lesions with standard-
ized uptake value (SUV) assessment and eventually PET and com-
puter tomography (CT) or magnetic resonance imaging (MRI) scan
fusion) are stored in the picture archiving and communication sys-
tem (PACS), which makes it accessible for clinical presentation
and further processing.
Analysis with reference
to clinical specialties
Due to the orientation of the Masaryk Memorial Cancer Institute,
the spectrum of examined patients from various fields of medicine
differs from the universally presented patient distribution (Figure 1):
 oncology 94%;
 neurology 4%;
 cardiology 2%.
Position emission tomography scan indications
There are 8 PET scan indications:
 differential diagnostics of foci of unknown character;
 examination of oncological patients in follow-up with history
or high risk of tumour relapse;
 examination in patients with elevated tumour marker levels and
no clinical signs of tumour and/or inconclusive findings from
basic imaging methods;
Figure 1. Patient distribution at the MMCI PET Centre.
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 therapeutic effect monitoring especially after chemotherapy
in cases where other treatment alternatives are available and/
/or in cases with highly demanding treatment (economy is-
sues, serious side effects, etc.);
 non-oncological indications;
 PET scans for radiotherapy planning;
 detailed examination prior to radical surgery (extended radi-
cality, high morbidity risk, and/or surgery expected to mar-
kedly affect the quality of life);
 staging of locoregionally advanced tumours with high dissemi-
nation risk following the standard adjuvant treatment
Image fusion
Following the installation of the Syngo software in February
2004, a software fusion of PET images with CT and/or MRI imag-
es has been performed at our PET Centre (Figure 2). A digital
form of the CT or MRI data in the DICOM 3.0 format is available for
image fusion via the PACS archive or a compact disc (in case of
external departments not connected via PACS).
The value of the image fusion lies in:
 better specification of foci depicted by the positron emission
tomography;
 localization of metabolically active tissue within the detected
foci and distinguishing of fibrotic tissue from viable cell re-
gions.
The image fusion is currently performed in approximately
a third of all PET examinations, and it became an inherent part of
the daily routine allowing for a marked improvement of the PET
scan finding evaluation.
Analysis of the FDG-PET findings
in correlation with tumour marker levels
In collaboration with the MMCI Department of Laboratory
Medicine we have analyzed the correlation of PET scan findings
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Figure 2. Number of PET examinations and PET/CT or PET/MRI image fusions. A. Year 2004: 4563 PET scans, 623 image fusions; B.  Year 2005 (up to
November 30th) : 5350 PET scans, 1479 image fusions.
A.
B.
162
Nuclear Medicine Review 2005, Vol. 8, No. 2
www.nmr.viamedica.pl
Occasional
surrey

with the tumour marker levels in patients undergoing repeated
FDG-PET examinations. The preliminary data suggests that
depending on the diagnosis the FDG-PET findings detect a re-
curring malignancy sooner than the tumour marker analysis in
1/5 up to 1/3 of the patients. Further analysis and statistical eval-
uation of the final data in connection with clinical assessment of
the patients in this study will specify the incorporation of the PET
examination within the algorithm of the diagnostic methods.
Application of FDG-PET in therapy control
The following points are followed closely and compared prior to
and after therapy in patients with repeated FDG-PET examinations:
 number and (to a certain extent) size of the glucose hyperme-
tabolism foci;
 metabolic activity of the foci via the SUV (standardized uptake
value) assessment.
Decrease in metabolic activity of the foci and/or reduction of
their number and size are interpreted as good therapeutic re-
sponse, and vice versa. A comparative study of FDG-PET find-
ings prior to and following treatment (Glivec) in a patient with GIST
(gastrointestinal stromal tumour) is presented as an example of
treatment efficacy evaluation in the Figure 3.
Application of FDG-PET in cardiology
We successfully use FDG-PET for viability evaluation of the left
ventricle myocardium prior to and following autologous stem cell trans-
plantation in patients overcoming an acute myocardial infarction (Fig-
ure 4). A total of 252 examinations have been performed in 111 pa-
tients up to the present date. A decrease in activity of more than 50%
within the afflicted part of the left ventricle in comparison with the
activity of reference myocardium is interpreted as a manifestation of
necrosis.
The activity of individual segments of the myocardium is eva-
luated with the help of the 4D-MSPECT cardiac analysis program
and use of the polar maps.
Application of FDG-PET in neurology
diagnostics
FDG-PET is performed:
 in patients with epilepsy resistant to pharmacotherapy, quali-
fying for stereotactic intervention. The examination is performed
during the interictal phase. The FDG-PET shows a decreased
metabolism area of the cerebral cortex at point of the epilep-
togenic zone;
 in patients with primary brain tumours or cerebral metastases
following radiotherapy or surgery. FDG-PET allows us to dis-
tinguish fibrotic scar tissue from an eventual tumour residuum
or relapse. Computed tomography and/or MRI findings in
a digital form enabling SW fusion of the images are necessary
for cerebral foci evaluation.
The Department of Nuclear Medicine and the Positron Emi-
ssion Tomography Centre of the Masaryk Memorial Cancer Insti-
tute currently employ five physicians specializing in nuclear med-
icine, one physician specializing in both nuclear medicine and
radiodiagnostics, nine laboratory assistants and one physicist. The
preparation of the radiopharmaceutical is performed by employ-
ees of the MMCI Pharmacy.
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Figure 4. Comparison of left ventricle myocardial activity before and after
the stem cell application in a patient overcoming a myocardial infarction.
A marked reduction of the extent of the necrosis apically and anteroseptally
is apparent following the stem cell application. Bottom row of individual
projections: FDG-PET prior to stem cell application. A lack of activity recorded
anteroseptally and apically. Top row of individual projections: increased
uptake in the affected myocardial regions following the stem cell application.
Figure 3. Bottom half of the figure: FDG-PET before therapy detects mul-
tiple foci of high tracer uptake in the area of the liver and the abdominal
cavity. The finding indicates the presence of viable tumour tissue. Top
half of the figure: control FDG-PET after therapy. Perfect clearance of the
metabolically active foci indicates a good response to therapy.
